Arrhythmogenic action of endothelin-11-31 through conversion to endothelin-11-21

Anjing Ren,Xin Yuan,Li Lin,Jing Xu,Ting Chen,Weizhong Wang,Xiaohong Yan,YongWen Qing,Chaoshu Tang,Wenjun Yuan
DOI: https://doi.org/10.3181/00379727-231-2310937
2006-01-01
Experimental Biology and Medicine
Abstract:Endothelin (ET)-11-21 is known to play an important role in the pathogenesis of acute ischemic arrhythmia. In the present study, we attempted to determine whether administration of ET-11-31 would result in arrhythmia in perfused isolated rat hearts. Forty-eight Sprague-Dawley rats weighing ∼250-350 g were randomized into 6 groups. Heart was isolated and perfused in a Langendorff mode. The effects of ET-11-31 on arrhythmia, heart rate, coronary flow, and heart function were analyzed. Perfusion with 1 nM ET-11-31 resulted in frequent ventricular ectopic beats (VEBs) and ventricular tachycardia (VT). Overall VEB was 128.0 (∼66.0-1015.0), and the arrhythmia score (AS) was 2.18 ± 0.87; both were significantly higher than those of the control group (P < 0.01). Pretreatment with perfusion of 10 nM of the ETA-receptor antagonist BQ 123 markedly attenuated the occurrence of VEB and VT induced by ET-11-31. AS in 10 nM BQ123 group was significantly lower than that in 1 nM ET-11-31 group (P < 0.01). The arrhythmia induced by 1 nM ET-11-31 was partially but significantly reduced by phosphoramidon (1 μM), a neutral endopeptidase/ET-converting enzyme inhibitor. ET-11-31 per se caused arrhythmia in perfused isolated rat hearts. This arrhythmogenic action is in part mediated by ETA receptor and may be attributed mainly to the conversion of ET-11-31 to ET-11-21. Copyright © 2006 by the Society for Experimental Biology and Medicine.
What problem does this paper attempt to address?